The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis
- PMID: 25008478
- DOI: 10.1016/j.crohns.2014.06.002
The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis
Abstract
Background and aims: Leukocyte-derived proteins in faeces, especially calprotectin, are increasingly used to assess disease activity in ulcerative colitis. The objectives of the present study were to assess the importance of factors related to the stool sampling procedure.
Methods: For 2 days, patients with active ulcerative colitis collected two stool samples at each bowel movement. The time of defecation, consistency and presence of blood were self-recorded in a diary. The variability in the concentrations of calprotectin during the day and between two consecutive days was assessed, as was the stability of calprotectin concentrations in samples stored at room temperature.
Results: Altogether, 18 patients collected 287 stool samples. The intraclass correlation coefficient in pairs of samples from 132 bowel movements was 0.79 (95% CI 0.48-0.90). The median individual coefficient of variation in samples collected during the same day was 52% (4-178). There was a correlation between the level of calprotectin and the time between bowel movements (r = 0.5; p = 0.013). After 3 days at room temperature the calprotectin concentrations in stool samples were unchanged, but after 7 days a significant (p < 0.01) decrease was found (mean 28%; 95% CI 0.10-0.47).
Conclusion: The present data reveal a great variability in the concentrations of calprotectin in stool samples collected during a single day. Since the levels of calprotectin increased with longer time between the bowel movements, it seems most appropriate to analyse stool from the first bowel movement in the morning. Moreover, storage of stool samples at room temperature for more than 3 days is not advisable.
Keywords: Calprotectin; Disease activity; Ulcerative colitis.
Copyright © 2014 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Comment in
-
IBD: Faecal calprotectin testing--the need for better standardization.Nat Rev Gastroenterol Hepatol. 2014 Oct;11(10):583-4. doi: 10.1038/nrgastro.2014.154. Epub 2014 Sep 9. Nat Rev Gastroenterol Hepatol. 2014. PMID: 25201042
Similar articles
-
Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure.Scand J Gastroenterol. 2016;51(5):548-55. doi: 10.3109/00365521.2015.1117650. Epub 2015 Dec 4. Scand J Gastroenterol. 2016. PMID: 26634305
-
High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?Inflamm Bowel Dis. 2015 May;21(5):1072-6. doi: 10.1097/MIB.0000000000000349. Inflamm Bowel Dis. 2015. PMID: 25793326
-
Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.J Crohns Colitis. 2015 Feb;9(2):164-9. doi: 10.1093/ecco-jcc/jju015. J Crohns Colitis. 2015. PMID: 25518057
-
Review article: faecal calprotectin and histologic remission in ulcerative colitis.Aliment Pharmacol Ther. 2020 Apr;51(7):689-698. doi: 10.1111/apt.15662. Epub 2020 Feb 12. Aliment Pharmacol Ther. 2020. PMID: 32048751
-
Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.J Crohns Colitis. 2013 Sep;7(8):670-7. doi: 10.1016/j.crohns.2013.02.014. Epub 2013 Mar 19. J Crohns Colitis. 2013. PMID: 23517932 No abstract available.
Cited by
-
Fecal calprotectin evaluation in patients with ulcerative colitis.Dig Dis Sci. 2015 Apr;60(4):1109-10. doi: 10.1007/s10620-015-3527-x. Epub 2015 Jan 14. Dig Dis Sci. 2015. PMID: 25586087 No abstract available.
-
Fecal Calprotectin in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease.Dig Dis Sci. 2017 Dec;62(12):3625-3626. doi: 10.1007/s10620-017-4799-0. Epub 2017 Oct 17. Dig Dis Sci. 2017. PMID: 29043593 No abstract available.
-
A combination of fecal calprotectin and human beta-defensin 2 facilitates diagnosis and monitoring of inflammatory bowel disease.Gut Microbes. 2021 Jan-Dec;13(1):1943288. doi: 10.1080/19490976.2021.1943288. Gut Microbes. 2021. PMID: 34313538 Free PMC article.
-
Crohn's disease management: translating STRIDE-II for UK clinical practice.Therap Adv Gastroenterol. 2024 Nov 7;17:17562848241280885. doi: 10.1177/17562848241280885. eCollection 2024. Therap Adv Gastroenterol. 2024. PMID: 39526077 Free PMC article. Review.
-
Fecal Calprotectin Elevations Associated with Food Intolerance/Malabsorption Are Significantly Reduced with Targeted Diets.Nutrients. 2023 Feb 27;15(5):1179. doi: 10.3390/nu15051179. Nutrients. 2023. PMID: 36904178 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical